jueves, 9 de junio de 2016
Cancer Currents Blog: Patient-Derived Antibody Appears to Selectively Target Tumor Cells, Spur Immune Attack
Patient-Derived Antibody Targets Tumor Cells - National Cancer Institute
Researchers have developed an antibody derived from patients with early-stage lung cancer that enlists the immune system to destroy cancer cells. The antibody killed tumor cells in cell lines of several different cancer types and slowed tumor growth in mouse models of brain and lung cancer without obvious evidence of side effects, the researchers reported May 5 in Cell Reports.